DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/cn48wt/case_study_autism) has announced the addition of the "Case Study: Autism Spectrum Disorders - Public Awareness and Physician Detailing will Drive Market Growth" report to their offering.
This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway.
To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals) are both approved in the US for the treatment of irritability associated with autistic disorder.
Scope
- Examination of key recommendations contained in published treatment guidelines for the management of ASDs.
- Overview of the treatment pathway and identification of three key points of influence that may be targeted by pharmaceutical companies.
- Discussion of key opportunities and threats facing existing and prospective players in the autism spectrum disorders market.
Key Topics Covered:
OVERVIEW
Originally posted here:
Research and Markets: Autism Spectrum Disorders - Public Awareness and Physician Detailing will Drive Market Growth